Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
6's will be clear soon
Go $DCAC
Agreed
Go $DCAC
Nice
WATCH FOR MAJOR NEWS NEXT WEEK
Go $DCAC
$DCAC will be another PR next week IMO
Go $DCAC
Nice
I think another follow up PR will be release next week IMO
Go $DCAC
$DCAC Daniels Corporate Advisory Company, Inc. Adds Industry Professional to Board of Directors
Feb 12, 2016
OTC Disclosure & News Service
Daniels Corporate Advisory Company, Inc. Adds Industry Professional to Board of Directors
NEW YORK, NY--(Marketwired - Feb 12, 2016) - Daniels Corporate Advisory Co., Inc. (OTCQB: DCAC) ("DCAC") is pleased to announce the addition of Patrick Johnson to its Board of Directors.
Patrick is the CEO and Director of Victura Construction Group Inc. (OTC PINK: VICT) ("VICT"), a vertically integrated holding company focused on strategic growth in the disaster recovery and restoration segments of the construction industry primarily in the Dallas/Fort Worth commercial and residential markets. His company's six operating subsidiaries have human assets that collectively have a history of performance achievements in industry partnerships.
"Patrick's function on our board will be to provide insight on strategic acquisitions within industry segments that service the construction, consumer products, oil and gas, software, and nutraceutical industries," states Arthur D. Viola, CEO of DCAC.
DCAC is exploring other areas of concentration with VICT in the areas of Water, Fire and Storm insurance Restoration and reconstruction services regarding property damage, which are paid by Insurance Proceeds, a recession-proof opportunity within the Construction Industry, in both residential and commercial markets.
"Any venture between the two firms or a target acquisition by Daniels would benefit the Parties through providing the ability to exponentially increase the footprint of existing business through Acquisition and/or Expansion," states Patrick Johnson, CEO of VICT.
Safe Harbor Statement
This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E and/or 27E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company's ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company's suppliers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.
Contact:
Daniels Corporate Advisory Co., Inc.
Arthur D. Viola
Chairman and CEO
(347) 242-2148
onewallstreetn@aol.com
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
Report TOS
Moderate
$DCAC Daniels Corporate Advisory Company, Inc. Adds Industry Professional to Board of Directors
Feb 12, 2016
OTC Disclosure & News Service
Daniels Corporate Advisory Company, Inc. Adds Industry Professional to Board of Directors
NEW YORK, NY--(Marketwired - Feb 12, 2016) - Daniels Corporate Advisory Co., Inc. (OTCQB: DCAC) ("DCAC") is pleased to announce the addition of Patrick Johnson to its Board of Directors.
Patrick is the CEO and Director of Victura Construction Group Inc. (OTC PINK: VICT) ("VICT"), a vertically integrated holding company focused on strategic growth in the disaster recovery and restoration segments of the construction industry primarily in the Dallas/Fort Worth commercial and residential markets. His company's six operating subsidiaries have human assets that collectively have a history of performance achievements in industry partnerships.
"Patrick's function on our board will be to provide insight on strategic acquisitions within industry segments that service the construction, consumer products, oil and gas, software, and nutraceutical industries," states Arthur D. Viola, CEO of DCAC.
DCAC is exploring other areas of concentration with VICT in the areas of Water, Fire and Storm insurance Restoration and reconstruction services regarding property damage, which are paid by Insurance Proceeds, a recession-proof opportunity within the Construction Industry, in both residential and commercial markets.
"Any venture between the two firms or a target acquisition by Daniels would benefit the Parties through providing the ability to exponentially increase the footprint of existing business through Acquisition and/or Expansion," states Patrick Johnson, CEO of VICT.
Safe Harbor Statement
This release includes "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E and/or 27E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company's ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company's suppliers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.
Contact:
Daniels Corporate Advisory Co., Inc.
Arthur D. Viola
Chairman and CEO
(347) 242-2148
onewallstreetn@aol.com
Copyright © 2016 Marketwired. All Rights Reserved
The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.
$DCAC PR hit shortly and hang tight
Go $DCAC
Nice
$PMCB Scientists have created insulin-producing cells that could replace injections
Australian scientists from the University of Technology, Sydney (UTS), have created a line of insulin-producing cells that could eliminate the need for Type 1 diabetics to inject themselves with insulin.
The development on its own is pretty impressive, but the cells, which are derived from liver cells, are now on their way to being incorporated to a world-first bio-artificial pancreas after being licensed by US biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has already acquired something called the Cell-in-a-Box® system, which is basically a tiny cellulose-based ‘capsule’ that can house artificial cells and integrate them into a human body. This platform can be used to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to, but after acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sites on targeting Type 1 diabetes.
Type 1 diabetes or juvenile-onset diabetes is an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents it from properly regulating the body’s blood glucose levels by releasing insulin.
The new cell line, called “Melligen” cells, is derived from human liver cells, which have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells.
“When a foetus develops, the liver and the pancreas form from the same endodermal origin,” explained Ann Simpson from UTS:Science, who has been developing the cells over the past 20 years, in a press release. Which means that they should have the potential to do the same things as one another.
Early lab trials have shown that the genetically modified Melligen cells are able to release insulin in direct response to the amount of glucose in their surroundings – something that could help type 1 diabetics to live without daily injections and regulate their blood sugar levels naturally.
“My team and I are excited by the prospect of working with PharmaCyte Biotech to eliminate daily injections for insulin-dependent diabetic patients,” said Simpson in the release.
The next step for the company is for PharmaCyte Biotech to embed clusters of the Melligen cells into the Cell-in-a-Box® capsule, which is around the size of a pin head.
These artificial pancreases will then be transplanted into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Several other groups are now working on artificial pancreases that use sensors under the skin, or even temporary tattoos to monitor blood glucose levels. But these systems all require a pump to control the amount of insulin required in response to these levels, rather than biologically sensitive cells.
It’s pretty exciting to see all the ground-breaking work on diabetes and insulin-producing cells finally be commercialized into a product that could directly change people’s lives.
—
Learn more here http://austrianova.com/healthcare/
$PMCB Scientists have created insulin-producing cells that could replace injections
Australian scientists from the University of Technology, Sydney (UTS), have created a line of insulin-producing cells that could eliminate the need for Type 1 diabetics to inject themselves with insulin.
The development on its own is pretty impressive, but the cells, which are derived from liver cells, are now on their way to being incorporated to a world-first bio-artificial pancreas after being licensed by US biotechnology company PharmaCyte Biotech last October.
PharmaCyte Biotech has already acquired something called the Cell-in-a-Box® system, which is basically a tiny cellulose-based ‘capsule’ that can house artificial cells and integrate them into a human body. This platform can be used to develop treatments for any disease where cells aren’t releasing the molecules they’re supposed to, but after acquiring the license to the insulin-producing cells, it’s clear that PharmaCyte Biotech has set their sites on targeting Type 1 diabetes.
Type 1 diabetes or juvenile-onset diabetes is an autoimmune disease that occurs when a person’s immune system attacks their pancreas’s islet cells and prevents it from properly regulating the body’s blood glucose levels by releasing insulin.
The new cell line, called “Melligen” cells, is derived from human liver cells, which have been genetically modified to take over the role of the pancreas’s insulin-producing islet cells.
“When a foetus develops, the liver and the pancreas form from the same endodermal origin,” explained Ann Simpson from UTS:Science, who has been developing the cells over the past 20 years, in a press release. Which means that they should have the potential to do the same things as one another.
Early lab trials have shown that the genetically modified Melligen cells are able to release insulin in direct response to the amount of glucose in their surroundings – something that could help type 1 diabetics to live without daily injections and regulate their blood sugar levels naturally.
“My team and I are excited by the prospect of working with PharmaCyte Biotech to eliminate daily injections for insulin-dependent diabetic patients,” said Simpson in the release.
The next step for the company is for PharmaCyte Biotech to embed clusters of the Melligen cells into the Cell-in-a-Box® capsule, which is around the size of a pin head.
These artificial pancreases will then be transplanted into animals to test whether they can effectively integrate into the body and regulate insulin levels. After that, they can begin testing the technology in humans.
Several other groups are now working on artificial pancreases that use sensors under the skin, or even temporary tattoos to monitor blood glucose levels. But these systems all require a pump to control the amount of insulin required in response to these levels, rather than biologically sensitive cells.
It’s pretty exciting to see all the ground-breaking work on diabetes and insulin-producing cells finally be commercialized into a product that could directly change people’s lives.
—
Learn more here http://austrianova.com/healthcare/
$PMCB PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
January 25, 2016
SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its Chief Executive Officer, Kenneth L. Waggoner, and its Chief Operating Officer, Dr. Gerald W. Crabtree, recently met with principals of Translational Drug Development (TD2) at TD2’s facilities in Scottsdale, Arizona. The meeting was held to discuss a number of aspects related to PharmaCyte’s upcoming clinical trial in pancreatic cancer and the structure of the Investigational New Drug Application (IND) that must be submitted to the FDA and found acceptable before the clinical trial can begin. PharmaCyte has contracted with TD2 to be the lead Contract Research Organization (CRO) to prepare for and conduct PharmaCyte’s clinical trial in pancreatic cancer.
In its clinical trial, PharmaCyte’s pancreatic cancer treatment (microcapsules containing live cells that convert the cancer prodrug ifosfamide into its cancer-killing form together with low doses of ifosfamide) will be compared with the combination of the cancer drug capecitabine plus radiation therapy. The clinical trial will be an open-label, “two-armed,” randomized multi-site trial.
The morning session addressed how the clinical trial will be structured and conducted. It was determined that there will be several cancer centers in the United States, with a number of study sites in Europe and possibly Australia. Discussions also dealt with suggested changes related to the number of patients in each arm of the trial, inclusion/exclusion criteria for patients that will be enrolled in the trial and possible sites at which the trial will be conducted.
The afternoon session focused on the IND and the timeline for filing it with the FDA. The afternoon session also included discussions related to the content and preparation of the Chemistry, Manufacturing and Controls (CMC) section of the IND. The CMC section is a pivotal part of the IND and will be a major focus of the FDA when it examines PharmaCyte’s IND submission. TD2 and Chamow & Associates (Chamow) will both prepare the CMC section of the application. Chamow has already performed an inspection and audit of Austrianova’s live-cell encapsulation facility in Bangkok, Thailand. That is the facility where the genetically modified live cells will be encapsulated using the Cell-in-a-Box® technology that are part of PharmaCyte’s pancreatic cancer treatment.
In commenting on the sessions at TD2, Waggoner stated, “These face-to-face meetings with TD2’s clinical trial team were extremely important and exceedingly helpful to PharmaCyte in finalizing the design of the clinical trial. We believe they will prove to be invaluable as we move forward with the preparations for our upcoming clinical trial in pancreatic cancer. The interactions that we had with the team at TD2 in this one day alone reinforce our belief that, in TD2, we have the finest CRO available in which to put our trust that PharmaCyte’s clinical trial will be prepared and conducted as well as it could be.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
$PMCB PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
January 25, 2016
SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that its Chief Executive Officer, Kenneth L. Waggoner, and its Chief Operating Officer, Dr. Gerald W. Crabtree, recently met with principals of Translational Drug Development (TD2) at TD2’s facilities in Scottsdale, Arizona. The meeting was held to discuss a number of aspects related to PharmaCyte’s upcoming clinical trial in pancreatic cancer and the structure of the Investigational New Drug Application (IND) that must be submitted to the FDA and found acceptable before the clinical trial can begin. PharmaCyte has contracted with TD2 to be the lead Contract Research Organization (CRO) to prepare for and conduct PharmaCyte’s clinical trial in pancreatic cancer.
In its clinical trial, PharmaCyte’s pancreatic cancer treatment (microcapsules containing live cells that convert the cancer prodrug ifosfamide into its cancer-killing form together with low doses of ifosfamide) will be compared with the combination of the cancer drug capecitabine plus radiation therapy. The clinical trial will be an open-label, “two-armed,” randomized multi-site trial.
The morning session addressed how the clinical trial will be structured and conducted. It was determined that there will be several cancer centers in the United States, with a number of study sites in Europe and possibly Australia. Discussions also dealt with suggested changes related to the number of patients in each arm of the trial, inclusion/exclusion criteria for patients that will be enrolled in the trial and possible sites at which the trial will be conducted.
The afternoon session focused on the IND and the timeline for filing it with the FDA. The afternoon session also included discussions related to the content and preparation of the Chemistry, Manufacturing and Controls (CMC) section of the IND. The CMC section is a pivotal part of the IND and will be a major focus of the FDA when it examines PharmaCyte’s IND submission. TD2 and Chamow & Associates (Chamow) will both prepare the CMC section of the application. Chamow has already performed an inspection and audit of Austrianova’s live-cell encapsulation facility in Bangkok, Thailand. That is the facility where the genetically modified live cells will be encapsulated using the Cell-in-a-Box® technology that are part of PharmaCyte’s pancreatic cancer treatment.
In commenting on the sessions at TD2, Waggoner stated, “These face-to-face meetings with TD2’s clinical trial team were extremely important and exceedingly helpful to PharmaCyte in finalizing the design of the clinical trial. We believe they will prove to be invaluable as we move forward with the preparations for our upcoming clinical trial in pancreatic cancer. The interactions that we had with the team at TD2 in this one day alone reinforce our belief that, in TD2, we have the finest CRO available in which to put our trust that PharmaCyte’s clinical trial will be prepared and conducted as well as it could be.”
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box®.” This unique and patented technology will be used as a platform upon which treatments for several types of cancer and diabetes are being developed.
PharmaCyte’s treatment for cancer involves encapsulating genetically modified live cells that convert an inactive chemotherapy drug (ifosfamide) into its active or “cancer-killing” form. These encapsulated live cells are placed as close to a cancerous tumor as possible. Once implanted in a patient, ifosfamide is then given intravenously at one-third the normal dose. The ifosfamide is carried by the circulatory system to where the encapsulated cells have been placed. When ifosfamide, which is normally activated in the liver, comes in contact with the encapsulated live cells, activation of the drug takes place at the source of the cancer without any side effects from the chemotherapy. This “targeted chemotherapy” has proven remarkably effective and safe to use in past clinical trials.
In addition to developing a novel treatment for cancer, PharmaCyte is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte plans to encapsulate a human cell line that has been genetically engineered to produce, store and release insulin in response to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements regarding PharmaCyte Biotech and its future events and results that involve inherent risks and uncertainties. The words "anticipate," "believe," "estimate," "expect," "intend," "plan" and similar expressions, as they relate to PharmaCyte or its management, are intended to identify forward-looking statements. Important factors, many of which are beyond the control of PharmaCyte, could cause actual results to differ materially from those set forth in the forward-looking statements. They include PharmaCyte's ability to continue as a going concern, delays or unsuccessful results in preclinical and clinical trials, flaws or defects regarding its product candidates, changes in relevant legislation or regulatory requirements, uncertainty of protection of PharmaCyte’s intellectual property and PharmaCyte’s continued ability to raise capital. PharmaCyte does not assume any obligation to update any of these forward-looking statements.
More information about PharmaCyte can be found at www.PharmaCyte.com. It can also be obtained by contacting Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
$PMCB Oncomed Pharmaceuticals Stumbles, But Pharmacyte Biotech Continues to Offer Hope in War on Pancreatic Cancer
Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) just reiterated today how tough pancreatic cancer is to beat. Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is also tough though, and continues to move forward with the cancer community's next big leap forward in the war on pancreatic cancer.
For fans and followers of Oncomed Pharmaceuticals Inc. (NASDAQ:OMED), the new trading week is getting started on the wrong foot. Although the company is going to continue on with this particular stage of the trial, the so-called ALPINE trial of it cancer immunology drug tarextumab as a therapy for pancreatic cancer doesn't look like it's going to meet its endpoint goal.
The announcement from OMED underscores just how tough pancreatic cancer is to beat; this is hardly the first instance of a well-known (and otherwise effective therapy) failing to do much good when it comes to treating the dreaded disease. Yet, the stumble for Oncomed Pharmaceuticals also puts a small biotech firm called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), as it's developing a pancreatic cancer treatment option that just might be the next, long-awaited quantum leap for this particular sliver of the oncology world.
Just for the record, in the phase 2 ALPINE trial, Oncomed Pharmaceuticals observed a distinct lack of benefit -- no progress in terms of progression-free survival or overall survival rates -- compared to a placebo. Such results contrast with trials recently performed by Pharmacyte Biotech.
Pharmacyte Biotech is the developer of a biotechnology called Cell-in-a-Box(r). In simplest terms, Cell-in-a-Box(r) is a means of encapsulating live cells -- cells grown to perform a particular function -- and implanting these pinhead-sized capsules in the body to perform a specific medical purpose. The technology has many applications, but PharmaCyte Biotech is furthest along in its development of the idea as a means of treating pancreatic cancer.
In phase 2 trials, PharmaCyte has shown that catalyzing a prodrug form of cancer-fighting therapy ifosfamide in the bloodstream physically near the cancer-ridden pancreas maximizes the effectiveness while minimizing the dosage. Ergo, this approach has proven superior to activation of the drug in the liver.
While potent, ifosfamide can also cause significant side effects when taken at doses large enough to effectively fight cancer. That's because liver-activated ifosfamide must make it all the way through the entire circulatory system before it reaches the pancreas. Most of the drug never reaches the pancreatic tumor. By activating the drug in the leg, though, the activated ifosfamide only needs to travel a few inches to reach the pancreas. The end result is an impressive degree of efficacy at only one-third the normal intravenous dosage of ifosfamide.
In a phase 1/2 trial examining the benefit of the Cell-in-a-Box(r) activation of ifosfamide versus the results gemcitabine would be able to achieve alone, the Pharmacyte approach improved the median survival timeframe from 28 to 44 weeks. Equally impressive is the fact that the number of one-year survivors increased from 18% to 36% of the study's patients.
The initial goal of Pharmacyte Biotech and its Cell-in-a-Box was as a frontline treatment, where it performed very well relative to current first-effort therapies of gemcitabine or a combination of gemcitabine and Abraxane. As the study progressed, however, the company recognized the drug ifosfamide when activated by its Cell-in-a-Box platform could effectively meet a much bigger and perhaps much more lucrative unmet need... pancreatic cancer patients for whom gemcitabine or the combination of gemcitabine and Abraxane was no longer effectively shrinking a tumor (even if it had stopped its growth).
That's about 40% of the pancreatic cancer patient population completely up for grabs, so to speak, as there is no "good" solution. Pharmacyte Biotech may be about to change that.
The next step is a redesigned phase 2 trial. The trials had to be reworked when the company recognized it would be better off aiming at a slightly different target. The new plans are taking shape right now, however, and the new phase 2 trial should begin soon. It's a reason to be excited about PMCB.
$PMCB Oncomed Pharmaceuticals Stumbles, But Pharmacyte Biotech Continues to Offer Hope in War on Pancreatic Cancer
Oncomed Pharmaceuticals Inc. (NASDAQ:OMED) just reiterated today how tough pancreatic cancer is to beat. Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is also tough though, and continues to move forward with the cancer community's next big leap forward in the war on pancreatic cancer.
For fans and followers of Oncomed Pharmaceuticals Inc. (NASDAQ:OMED), the new trading week is getting started on the wrong foot. Although the company is going to continue on with this particular stage of the trial, the so-called ALPINE trial of it cancer immunology drug tarextumab as a therapy for pancreatic cancer doesn't look like it's going to meet its endpoint goal.
The announcement from OMED underscores just how tough pancreatic cancer is to beat; this is hardly the first instance of a well-known (and otherwise effective therapy) failing to do much good when it comes to treating the dreaded disease. Yet, the stumble for Oncomed Pharmaceuticals also puts a small biotech firm called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), as it's developing a pancreatic cancer treatment option that just might be the next, long-awaited quantum leap for this particular sliver of the oncology world.
Just for the record, in the phase 2 ALPINE trial, Oncomed Pharmaceuticals observed a distinct lack of benefit -- no progress in terms of progression-free survival or overall survival rates -- compared to a placebo. Such results contrast with trials recently performed by Pharmacyte Biotech.
Pharmacyte Biotech is the developer of a biotechnology called Cell-in-a-Box(r). In simplest terms, Cell-in-a-Box(r) is a means of encapsulating live cells -- cells grown to perform a particular function -- and implanting these pinhead-sized capsules in the body to perform a specific medical purpose. The technology has many applications, but PharmaCyte Biotech is furthest along in its development of the idea as a means of treating pancreatic cancer.
In phase 2 trials, PharmaCyte has shown that catalyzing a prodrug form of cancer-fighting therapy ifosfamide in the bloodstream physically near the cancer-ridden pancreas maximizes the effectiveness while minimizing the dosage. Ergo, this approach has proven superior to activation of the drug in the liver.
While potent, ifosfamide can also cause significant side effects when taken at doses large enough to effectively fight cancer. That's because liver-activated ifosfamide must make it all the way through the entire circulatory system before it reaches the pancreas. Most of the drug never reaches the pancreatic tumor. By activating the drug in the leg, though, the activated ifosfamide only needs to travel a few inches to reach the pancreas. The end result is an impressive degree of efficacy at only one-third the normal intravenous dosage of ifosfamide.
In a phase 1/2 trial examining the benefit of the Cell-in-a-Box(r) activation of ifosfamide versus the results gemcitabine would be able to achieve alone, the Pharmacyte approach improved the median survival timeframe from 28 to 44 weeks. Equally impressive is the fact that the number of one-year survivors increased from 18% to 36% of the study's patients.
The initial goal of Pharmacyte Biotech and its Cell-in-a-Box was as a frontline treatment, where it performed very well relative to current first-effort therapies of gemcitabine or a combination of gemcitabine and Abraxane. As the study progressed, however, the company recognized the drug ifosfamide when activated by its Cell-in-a-Box platform could effectively meet a much bigger and perhaps much more lucrative unmet need... pancreatic cancer patients for whom gemcitabine or the combination of gemcitabine and Abraxane was no longer effectively shrinking a tumor (even if it had stopped its growth).
That's about 40% of the pancreatic cancer patient population completely up for grabs, so to speak, as there is no "good" solution. Pharmacyte Biotech may be about to change that.
The next step is a redesigned phase 2 trial. The trials had to be reworked when the company recognized it would be better off aiming at a slightly different target. The new plans are taking shape right now, however, and the new phase 2 trial should begin soon. It's a reason to be excited about PMCB.
$PMCB What Are Clinical Stage Biotech Stocks?
Many small cap biotech stocks like Pharmacyte Biotech Inc (OTCQB: PMCB) call themselves “clinical stage biotech stock.” Here is what you need to know when a biotech stock says they are in the clinical stage.
If you are an investor new to biotech investing, you might be wondering what is meant when a small cap biotech stock like Pharmacyte Biotech Inc (OTCQB: PMCB) calls themselves a “clinical stage biotech stock” or company. After all, many small cap biotech stocks like Pharmacyte Biotech are still in the clinical stage; but such stocks tend to not be the best of investments for risk adverse or novice investors.
What Are Clinical Stage Biotech Stocks?
When a small cap biotech stock calls themselves a clinical stage biotech stock, it usually means they do not yet have any drugs or treatments approved by the FDA or other appropriate regulatory authorities in other countries. For that reason, you should be aware of and have an understanding of the phases of drug development:
An Investigational New Drug Application (IND) is made to the FDA showing results of any study done in the laboratory.
Clinical Phase I involves studies performed on a small group of healthy volunteers to see how a new drug is metabolized in the human body as well as to determine the dose and dosage interval that will have a positive effect on the disease or problem without unwanted side-effects.
Clinical Phase II involves treating a larger group of patients to demonstrate a new drug's efficacy and to confirm its safety with comparisons often being made with another group receiving inactive placebo treatment.
Clinical Phase III’s main goal is to prove that any promising effects seen in Phase II can also be obtained in larger patient groups with great importance being attached to safety issues, documentation and production preparations.
Submission of a New Drug Application to the FDA will usually occur at this point and it should be kept in mind there is still no guarantee that the FDA will approve something – even if Phase I to Phase III trials or studies resulted in positive data or results. Sometime the FDA will ask for further studies or clarifications.
Keep in mind that most drug clinical trials will fail to achieve their goals – meaning you should look for clinical stage biotech stocks that have diversified drug pipelines or are building drug platforms that have the potential to treat multiple conditions.
With that said and if you are a risk adverse investor, you would be better off buying established biotech stocks that are beyond the clinical stage with approved drugs, are profitable and have developed drug pipelines. The downside about such biotech stocks is that they are already on Wall Street's radar and the trading screen of every other biotech stock trader/investor out there – meaning you have probably missed the big homerun, share pop or lottery ticket winner.
Clinical Stage Biotech Stock Example: PharmaCyte Biotech
Small cap PharmaCyte Biotech is a good example of a clinical stage biotechnology company that’s probably still off the radar screen of Wall Street and most biotech investors as its still trading on the OTC. PharmaCyte Biotech is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box.
More specifically, the technology encloses living cells in protective “cocoons” or “capsules” about the size of the head of a pin. The live cells inside the Cell-in-a-Box® capsules are then nourished and thrive while the capsules are in the body and are protected from attack by the body’s immune system because they cannot escape from the capsules and immune system cells cannot enter the capsules and destroy them.
PharmaCyte Biotech’s Cell-in-a-Box encapsulation differs from those produced by others as competitors use substances such as alginate (a seaweed derivative) or chitosan whereas PMCB’s capsules are made principally of cellulose, a bio-inert material in the human body.
For the second half of the year, PharmaCyte Biotech has been busy making various announcements worth noting by investors:
$PMCB recent news/filings
## source: finance.yahoo.com
Mon, 25 Jan 2016 17:47:09 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[at noodls] - SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) - PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its ...
read full: http://www.publicnow.com/view/28F42A22A64DD4473B7669A8E686AE2F2A16F544
*********************************************************
Mon, 25 Jan 2016 14:25:00 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[GlobeNewswire] - SILVER SPRING, Md., Jan. 25, 2016-- PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation ...
read full: http://finance.yahoo.com/news/pharmacyte-executives-meet-translational-drug-142500942.html
*********************************************************
Sat, 23 Jan 2016 18:04:15 GMT ~ PHARMACYTE BIOTECH, INC. Financials
read full: http://finance.yahoo.com/q/is?s=pmcb
*********************************************************
Thu, 21 Jan 2016 14:12:00 GMT ~ The Road Ahead -- Featured Research on SpectraScience, Pharmacyte Biotech, Silvercorp Metals and Aytu BioScience
[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraScience ...
read full: http://finance.yahoo.com/news/road-ahead-featured-research-spectrascience-141200909.html
*********************************************************
Tue, 19 Jan 2016 22:34:55 GMT ~ PHARMACYTE BIOTECH, INC. Files SEC form 10-K/A, Annual Report
read full: http://biz.yahoo.com/e/160119/pmcb10-k_a.html
*********************************************************
PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board Marketwired (Tue, Jul 21)
PharmaCyte Biotech would be down 62.8% since the start of the year – not necessarily a bad sign as the stock is a clinical stage biotech. Nevertheless, shares are still up 346.7% over the past five years.
$PMCB What Are Clinical Stage Biotech Stocks?
Many small cap biotech stocks like Pharmacyte Biotech Inc (OTCQB: PMCB) call themselves “clinical stage biotech stock.” Here is what you need to know when a biotech stock says they are in the clinical stage.
If you are an investor new to biotech investing, you might be wondering what is meant when a small cap biotech stock like Pharmacyte Biotech Inc (OTCQB: PMCB) calls themselves a “clinical stage biotech stock” or company. After all, many small cap biotech stocks like Pharmacyte Biotech are still in the clinical stage; but such stocks tend to not be the best of investments for risk adverse or novice investors.
What Are Clinical Stage Biotech Stocks?
When a small cap biotech stock calls themselves a clinical stage biotech stock, it usually means they do not yet have any drugs or treatments approved by the FDA or other appropriate regulatory authorities in other countries. For that reason, you should be aware of and have an understanding of the phases of drug development:
An Investigational New Drug Application (IND) is made to the FDA showing results of any study done in the laboratory.
Clinical Phase I involves studies performed on a small group of healthy volunteers to see how a new drug is metabolized in the human body as well as to determine the dose and dosage interval that will have a positive effect on the disease or problem without unwanted side-effects.
Clinical Phase II involves treating a larger group of patients to demonstrate a new drug's efficacy and to confirm its safety with comparisons often being made with another group receiving inactive placebo treatment.
Clinical Phase III’s main goal is to prove that any promising effects seen in Phase II can also be obtained in larger patient groups with great importance being attached to safety issues, documentation and production preparations.
Submission of a New Drug Application to the FDA will usually occur at this point and it should be kept in mind there is still no guarantee that the FDA will approve something – even if Phase I to Phase III trials or studies resulted in positive data or results. Sometime the FDA will ask for further studies or clarifications.
Keep in mind that most drug clinical trials will fail to achieve their goals – meaning you should look for clinical stage biotech stocks that have diversified drug pipelines or are building drug platforms that have the potential to treat multiple conditions.
With that said and if you are a risk adverse investor, you would be better off buying established biotech stocks that are beyond the clinical stage with approved drugs, are profitable and have developed drug pipelines. The downside about such biotech stocks is that they are already on Wall Street's radar and the trading screen of every other biotech stock trader/investor out there – meaning you have probably missed the big homerun, share pop or lottery ticket winner.
Clinical Stage Biotech Stock Example: PharmaCyte Biotech
Small cap PharmaCyte Biotech is a good example of a clinical stage biotechnology company that’s probably still off the radar screen of Wall Street and most biotech investors as its still trading on the OTC. PharmaCyte Biotech is focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box.
More specifically, the technology encloses living cells in protective “cocoons” or “capsules” about the size of the head of a pin. The live cells inside the Cell-in-a-Box® capsules are then nourished and thrive while the capsules are in the body and are protected from attack by the body’s immune system because they cannot escape from the capsules and immune system cells cannot enter the capsules and destroy them.
PharmaCyte Biotech’s Cell-in-a-Box encapsulation differs from those produced by others as competitors use substances such as alginate (a seaweed derivative) or chitosan whereas PMCB’s capsules are made principally of cellulose, a bio-inert material in the human body.
For the second half of the year, PharmaCyte Biotech has been busy making various announcements worth noting by investors:
$PMCB recent news/filings
## source: finance.yahoo.com
Mon, 25 Jan 2016 17:47:09 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[at noodls] - SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) - PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its ...
read full: http://www.publicnow.com/view/28F42A22A64DD4473B7669A8E686AE2F2A16F544
*********************************************************
Mon, 25 Jan 2016 14:25:00 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[GlobeNewswire] - SILVER SPRING, Md., Jan. 25, 2016-- PharmaCyte Biotech, Inc., a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation ...
read full: http://finance.yahoo.com/news/pharmacyte-executives-meet-translational-drug-142500942.html
*********************************************************
Sat, 23 Jan 2016 18:04:15 GMT ~ PHARMACYTE BIOTECH, INC. Financials
read full: http://finance.yahoo.com/q/is?s=pmcb
*********************************************************
Thu, 21 Jan 2016 14:12:00 GMT ~ The Road Ahead -- Featured Research on SpectraScience, Pharmacyte Biotech, Silvercorp Metals and Aytu BioScience
[Accesswire] - NEW YORK, NY / ACCESSWIRE / January 21, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: SpectraScience ...
read full: http://finance.yahoo.com/news/road-ahead-featured-research-spectrascience-141200909.html
*********************************************************
Tue, 19 Jan 2016 22:34:55 GMT ~ PHARMACYTE BIOTECH, INC. Files SEC form 10-K/A, Annual Report
read full: http://biz.yahoo.com/e/160119/pmcb10-k_a.html
*********************************************************
PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board Marketwired (Tue, Jul 21)
PharmaCyte Biotech would be down 62.8% since the start of the year – not necessarily a bad sign as the stock is a clinical stage biotech. Nevertheless, shares are still up 346.7% over the past five years.
$PMCB Pharmacyte Biotech is Poised to Rock the Diabetes Treatment Boat
After a century of maintaining the status quo, Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is working on a quantum leap in the treatment of diabetes.
While the last few decades have seen some amazing advances in medicine, one area that hasn't changed much - if at all - is diabetes treatments. The current standard of care is insulin injections, and though they've certainly improved since first being introduced back in the 1920's the basic premise is no different now than it was then. A small, up-and-coming biotech company called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), may be about to change the diabetes treatment paradigm.
Diabetes, in simplest terms, is an excess of glucose (sugar) in the bloodstream. Normally the human body can process and remove this glucose with insulin produced naturally produced by the pancreas. For diabetics, however, the insulin-producing beta cells in the pancreas are destroyed by that body's immune system. Though type 2 diabetes can often be treated by weight loss and better dietary habits, type 1 diabetes - "the bad one" - cannot be self-regulated by diet and exercise.
Proposed solutions to the type 1 diabetes problem have been varied, and each has its merits.
The simplest solution (and the one still primarily used) was, as noted, is injecting insulin into the diabetic patient's bloodstream. This is the solution Novo Nordisk A/S (NYSE:NVO) introduced nearly a century ago. The downside? Even a small needle is still a needle, and the required dosage is forever changing with a diabetic's glucose levels.
MannKind Corporation (NASDAQ:MNKD) arguably introduced the biggest leap in the world of insulin treatments last year, winning the FDA's approval for AFREZZA... and inhaled form of insulin. While this approach circumvents the needle, questions remain over the long-term safety of delivering insulin through the lungs.
And in between those two milestones, several companies toyed with the idea of depositing or replacing the islet cells in the pancreas as a therapy for type 1 diabetes, which would effectively serve as a cure for the disease. These ideas showed promise too, but were largely problematic. Either these cells were still ultimately attacked by the immune system, or the mechanical structure required to place them in the pancreas failed.
To this day, the only viable treatment of type 1 diabetes is the original one... forcing insulin into the bloodstream from outside the body, one way or another. Pharmacyte Biotech may be about to change this with what could effectively be seen as a cure for the disease.
The technology is called Cell-in-a-Box. Pharmacyte Biotech developed it as a means of depositing living, normally-functioning cells into a particular part of the body where their presence would have a therapeutic effect. In this case, the cells "in the box" would be insulin-producing islet cells placed within the pancreas. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
It's an idea that's been tried before, but as was noted, it's an idea that's generally failed one way or another. The game-changer Pharmacyte brings to the table, however, is the Cell-in-a-Box encapsulation biotechnology.
The key to Cell-in-a-Box is the combination of the right polymers added to the mix in the right way at the right time.
The process starts out with a mix of live cells (insulin-producing pancreatic cells in this case) and a polymer which is then passed through a droplet-forming device into a bath of another proprietary polymer. When the two polymers meet, a membrane is formed, with the living cells inside of it. This membrane keeps the cells in, lets insulin out, lets nutrients in, and most important, prevents the body's immune system from destroying these cells.... something most previous encapsulation attempts couldn't do.
And that's the proverbial quantum leap for diabetics - an encapsulation technology that actually works for the long haul.
There's still work to be done. Cell-in-a-Box as a treatment pathway for type 1 diabetes is currently in the preclinical research phase, though it was recently validated as a safe biotechnology by University of Veterinary Medicine Vienna. Then again, its confirmed safety can't even be counted as a pleasant surprise, as it's the same delivery technology that's now part of a phase 2 study as a treatment means for pancreatic cancer.
Whatever the case, Pharmacyte Biotech is one step closer to beginning human clinical trials of the diabetes treatment approach. That alone could prove catalytic for its stock, as it has the potential to change the way the world thinks about treating diabetes.
$PMCB Pharmacyte Biotech is Poised to Rock the Diabetes Treatment Boat
After a century of maintaining the status quo, Pharmacyte Biotech Inc. (OTCMKTS:PMCB) is working on a quantum leap in the treatment of diabetes.
While the last few decades have seen some amazing advances in medicine, one area that hasn't changed much - if at all - is diabetes treatments. The current standard of care is insulin injections, and though they've certainly improved since first being introduced back in the 1920's the basic premise is no different now than it was then. A small, up-and-coming biotech company called Pharmacyte Biotech Inc. (OTCMKTS:PMCB), may be about to change the diabetes treatment paradigm.
Diabetes, in simplest terms, is an excess of glucose (sugar) in the bloodstream. Normally the human body can process and remove this glucose with insulin produced naturally produced by the pancreas. For diabetics, however, the insulin-producing beta cells in the pancreas are destroyed by that body's immune system. Though type 2 diabetes can often be treated by weight loss and better dietary habits, type 1 diabetes - "the bad one" - cannot be self-regulated by diet and exercise.
Proposed solutions to the type 1 diabetes problem have been varied, and each has its merits.
The simplest solution (and the one still primarily used) was, as noted, is injecting insulin into the diabetic patient's bloodstream. This is the solution Novo Nordisk A/S (NYSE:NVO) introduced nearly a century ago. The downside? Even a small needle is still a needle, and the required dosage is forever changing with a diabetic's glucose levels.
MannKind Corporation (NASDAQ:MNKD) arguably introduced the biggest leap in the world of insulin treatments last year, winning the FDA's approval for AFREZZA... and inhaled form of insulin. While this approach circumvents the needle, questions remain over the long-term safety of delivering insulin through the lungs.
And in between those two milestones, several companies toyed with the idea of depositing or replacing the islet cells in the pancreas as a therapy for type 1 diabetes, which would effectively serve as a cure for the disease. These ideas showed promise too, but were largely problematic. Either these cells were still ultimately attacked by the immune system, or the mechanical structure required to place them in the pancreas failed.
To this day, the only viable treatment of type 1 diabetes is the original one... forcing insulin into the bloodstream from outside the body, one way or another. Pharmacyte Biotech may be about to change this with what could effectively be seen as a cure for the disease.
The technology is called Cell-in-a-Box. Pharmacyte Biotech developed it as a means of depositing living, normally-functioning cells into a particular part of the body where their presence would have a therapeutic effect. In this case, the cells "in the box" would be insulin-producing islet cells placed within the pancreas. Just like a patient's own cells would detect the presence of glucose and begin producing insulin, the cells inside the encapsulation are capable of sensing high levels of glucose and produce an appropriate amount of insulin.
It's an idea that's been tried before, but as was noted, it's an idea that's generally failed one way or another. The game-changer Pharmacyte brings to the table, however, is the Cell-in-a-Box encapsulation biotechnology.
The key to Cell-in-a-Box is the combination of the right polymers added to the mix in the right way at the right time.
The process starts out with a mix of live cells (insulin-producing pancreatic cells in this case) and a polymer which is then passed through a droplet-forming device into a bath of another proprietary polymer. When the two polymers meet, a membrane is formed, with the living cells inside of it. This membrane keeps the cells in, lets insulin out, lets nutrients in, and most important, prevents the body's immune system from destroying these cells.... something most previous encapsulation attempts couldn't do.
And that's the proverbial quantum leap for diabetics - an encapsulation technology that actually works for the long haul.
There's still work to be done. Cell-in-a-Box as a treatment pathway for type 1 diabetes is currently in the preclinical research phase, though it was recently validated as a safe biotechnology by University of Veterinary Medicine Vienna. Then again, its confirmed safety can't even be counted as a pleasant surprise, as it's the same delivery technology that's now part of a phase 2 study as a treatment means for pancreatic cancer.
Whatever the case, Pharmacyte Biotech is one step closer to beginning human clinical trials of the diabetes treatment approach. That alone could prove catalytic for its stock, as it has the potential to change the way the world thinks about treating diabetes.
$PMCB ~ PharmaCyte Biotech, Inc. due diligence report
$PMCB recent news/filings
## source: finance.yahoo.com
Mon, 08 Feb 2016 14:00:00 GMT ~ Johnson & Johnson and Big Pharma Could Find a Diabetes "Cure" With PharmaCyte Biotech's Type 1 Diabetes Treatment
[Marketwired] - Johnson & Johnson , like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, J&J's head of global innovation, ...
read full: http://finance.yahoo.com/news/johnson-johnson-big-pharma-could-140000750.html
*********************************************************
Tue, 02 Feb 2016 12:30:00 GMT ~ Where are the Traders Headed - Analyst Notes on CD International Enterprises, Valley High Mining, Pharmacyte Biotech and Bombardier
[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 2, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CD International ...
read full: http://finance.yahoo.com/news/where-traders-headed-analyst-notes-123000207.html
*********************************************************
Mon, 01 Feb 2016 14:05:00 GMT ~ Trading Ahead of Upcoming Developments -- New Research on Trans-Pacific Aerospace Company, Pharmacyte Biotech, First Mining Finance, and Accretive Health
[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Trans-Pacific ...
read full: http://finance.yahoo.com/news/trading-ahead-upcoming-developments-research-140500683.html
*********************************************************
Thu, 28 Jan 2016 12:43:00 GMT ~ Presidential Elections Put Cannabis & Cannabis Stocks To Watch, Center Stage In 2016
[Accesswire] - CORAL GABLES, FL / ACCESSWIRE / January 28, 2016 / There's no debating the wild ride the marijuana industry has had since legalization for recreational use went live in 2014. Now two years later we are ...
read full: http://finance.yahoo.com/news/presidential-elections-put-cannabis-cannabis-124300853.html
*********************************************************
Mon, 25 Jan 2016 17:47:09 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[at noodls] - SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) - PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its ...
read full: http://www.publicnow.com/view/28F42A22A64DD4473B7669A8E686AE2F2A16F544
*********************************************************
$PMCB charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$PMCB company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/PMCB/company-info
Ticker: $PMCB
OTC Market Place: OTCQB
CIK code: 0001157075
Company name: PharmaCyte Biotech, Inc.
Company website: http://http://www.PharmaCyte.com
Incorporated In: NV, USA
Business Description: PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as \"Cell-in-a-Box\" This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and its symptoms, and diabetes are being developed. PharmaCyte Biotech's treatment for solid tumor cancers involves encapsulating modified live cells capable of converting the prodrug ifosfamide into its active or \"cancer-killing\" form. These encapsulated live cells are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. Ifosfamide is then given intravenously at one third the normal dose to eliminate adverse side effects. When the ifosfamide comes in contact with the encapsulated live cells through the circulatory system, the activation of the drug takes place at or near the tumor. This \"targeted chemotherapy\" has proven remarkably effective and safe to use in past clinical trials. PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of the Cannabis plant. It is examining ways to exploit the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of Cannabis, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. In addition to developing treatments for pancreatic and other cancers, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin on demand at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology.Less >>
$PMCB share structure
## source: otcmarkets.com
Market Value: $51,807,051 a/o Feb 08, 2016
Shares Outstanding: 750,826,823 a/o Dec 10, 2015
Float: 529,206,849 a/o Aug 26, 2014
Authorized Shares: 1,490,000,000 a/o Aug 26, 2014
Par Value: 0.0001
$PMCB extra dd links
Company name: PharmaCyte Biotech, Inc.
Company website: http://http://www.PharmaCyte.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PMCB+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PMCB+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PMCB+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/news - http://finance.yahoo.com/q/h?s=PMCB+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PMCB/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PMCB+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PMCB
DTCC (dtcc.com): http://search2.dtcc.com/?q=PharmaCyte+Biotech%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=PharmaCyte+Biotech%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=PharmaCyte+Biotech%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://http://www.PharmaCyte.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://http://www.PharmaCyte.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://http://www.PharmaCyte.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PMCB
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001157075&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PMCB&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PMCB
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PMCB+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PMCB+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PMCB
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PMCB
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PMCB+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PMCB/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PMCB+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PMCB.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PMCB
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PMCB
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PMCB
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PMCB:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PMCB
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PMCB
$PMCB ~ PharmaCyte Biotech, Inc. due diligence report
$PMCB recent news/filings
## source: finance.yahoo.com
Mon, 08 Feb 2016 14:00:00 GMT ~ Johnson & Johnson and Big Pharma Could Find a Diabetes "Cure" With PharmaCyte Biotech's Type 1 Diabetes Treatment
[Marketwired] - Johnson & Johnson , like much of the biopharmaceutical industry worldwide, is aware of the desperate necessity for a Type 1 diabetes treatment. In fact, Diego Miralles, J&J's head of global innovation, ...
read full: http://finance.yahoo.com/news/johnson-johnson-big-pharma-could-140000750.html
*********************************************************
Tue, 02 Feb 2016 12:30:00 GMT ~ Where are the Traders Headed - Analyst Notes on CD International Enterprises, Valley High Mining, Pharmacyte Biotech and Bombardier
[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 2, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: CD International ...
read full: http://finance.yahoo.com/news/where-traders-headed-analyst-notes-123000207.html
*********************************************************
Mon, 01 Feb 2016 14:05:00 GMT ~ Trading Ahead of Upcoming Developments -- New Research on Trans-Pacific Aerospace Company, Pharmacyte Biotech, First Mining Finance, and Accretive Health
[Accesswire] - NEW YORK, NY / ACCESSWIRE / February 1, 2016 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Trans-Pacific ...
read full: http://finance.yahoo.com/news/trading-ahead-upcoming-developments-research-140500683.html
*********************************************************
Thu, 28 Jan 2016 12:43:00 GMT ~ Presidential Elections Put Cannabis & Cannabis Stocks To Watch, Center Stage In 2016
[Accesswire] - CORAL GABLES, FL / ACCESSWIRE / January 28, 2016 / There's no debating the wild ride the marijuana industry has had since legalization for recreational use went live in 2014. Now two years later we are ...
read full: http://finance.yahoo.com/news/presidential-elections-put-cannabis-cannabis-124300853.html
*********************************************************
Mon, 25 Jan 2016 17:47:09 GMT ~ PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial
[at noodls] - SILVER SPRING, Md., Jan. 25, 2016 (GLOBE NEWSWIRE) - PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its ...
read full: http://www.publicnow.com/view/28F42A22A64DD4473B7669A8E686AE2F2A16F544
*********************************************************
$PMCB charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$PMCB company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/PMCB/company-info
Ticker: $PMCB
OTC Market Place: OTCQB
CIK code: 0001157075
Company name: PharmaCyte Biotech, Inc.
Company website: http://http://www.PharmaCyte.com
Incorporated In: NV, USA
Business Description: PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology known as \"Cell-in-a-Box\" This unique and patented technology will be used as a platform upon which treatments for several types of cancer, including advanced, inoperable pancreatic cancer and its symptoms, and diabetes are being developed. PharmaCyte Biotech's treatment for solid tumor cancers involves encapsulating modified live cells capable of converting the prodrug ifosfamide into its active or \"cancer-killing\" form. These encapsulated live cells are placed as close to the tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer. Ifosfamide is then given intravenously at one third the normal dose to eliminate adverse side effects. When the ifosfamide comes in contact with the encapsulated live cells through the circulatory system, the activation of the drug takes place at or near the tumor. This \"targeted chemotherapy\" has proven remarkably effective and safe to use in past clinical trials. PharmaCyte Biotech is also developing treatments for cancer based upon chemical constituents of the Cannabis plant. It is examining ways to exploit the benefits of Cell-in-a-Box technology in optimizing the anticancer effectiveness of Cannabis, while minimizing or outright eliminating the debilitating side effects usually associated with cancer treatments. In addition to developing treatments for pancreatic and other cancers, PharmaCyte Biotech is developing a treatment for Type 1 diabetes and Type 2 insulin-dependent diabetes. PharmaCyte Biotech plans to encapsulate a human cell line which has been genetically engineered to produce, store and secrete insulin on demand at levels in proportion to the levels of blood sugar in the human body. The encapsulation will be done using the Cell-in-a-Box technology.Less >>
$PMCB share structure
## source: otcmarkets.com
Market Value: $51,807,051 a/o Feb 08, 2016
Shares Outstanding: 750,826,823 a/o Dec 10, 2015
Float: 529,206,849 a/o Aug 26, 2014
Authorized Shares: 1,490,000,000 a/o Aug 26, 2014
Par Value: 0.0001
$PMCB extra dd links
Company name: PharmaCyte Biotech, Inc.
Company website: http://http://www.PharmaCyte.com
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=PMCB+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=PMCB+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=PMCB+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/news - http://finance.yahoo.com/q/h?s=PMCB+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/PMCB/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=PMCB+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/PMCB
DTCC (dtcc.com): http://search2.dtcc.com/?q=PharmaCyte+Biotech%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=PharmaCyte+Biotech%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=PharmaCyte+Biotech%2C+Inc.&x=0&y=0
WHOIS (domaintools.com): http://whois.domaintools.com/http://http://www.PharmaCyte.com
Alexa (alexa.com): http://www.alexa.com/siteinfo/http://http://www.PharmaCyte.com#
Corporate website internet archive (archive.org): http://web.archive.org/web/*/http://http://www.PharmaCyte.com
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/PMCB
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001157075&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=PMCB&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=PMCB
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=PMCB+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=PMCB+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=PMCB
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=PMCB
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=PMCB+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/PMCB/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=PMCB+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/PMCB.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=PMCB
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/PMCB/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/PMCB/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/PMCB
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/PMCB
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/PMCB:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=PMCB
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=PMCB
$VPCO Nasdaq Halts Vapor Corp.
Source: GlobeNewswire Inc.
The Nasdaq Stock Market® (Nasdaq:NDAQ) announced that trading was halted today in Vapor Corp. (Nasdaq:VPCO) at 15:43:47 Eastern Time for "additional information requested" from the company at a last price of $0.0006.
Trading will remain halted until Vapor Corp. has fully satisfied Nasdaq’s request for additional information.
For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.
For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.
NDAQO
Nasdaq Media Contact:
Peter Gau
+1.212.231.5475
Peter.Gau@nasdaq.com
Primary Logo
$VPCO Nasdaq Halts Vapor Corp.
Source: GlobeNewswire Inc.
The Nasdaq Stock Market® (Nasdaq:NDAQ) announced that trading was halted today in Vapor Corp. (Nasdaq:VPCO) at 15:43:47 Eastern Time for "additional information requested" from the company at a last price of $0.0006.
Trading will remain halted until Vapor Corp. has fully satisfied Nasdaq’s request for additional information.
For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site.
For more information about The Nasdaq Stock Market, visit the Nasdaq Web site at http://www.nasdaq.com.
NDAQO
Nasdaq Media Contact:
Peter Gau
+1.212.231.5475
Peter.Gau@nasdaq.com
Primary Logo
Yeah...need better news from them
$OCFN anyone know when they will be release news?
$DCAC Trader's Cheat Sheet
http://www.barchart.com/cheatsheet.php?sym=DCAC